Anatibant (LF 16-0687) is a novel, potent and non-peptide bradykinin B2 receptor antagonist that reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury. The inhibition of bradykinin B2 receptors seems to be a promising treatment option for traumatic brain injury.

纯度：≥98%

CAS：209733-45-9